Description
About this webinar
A number of solubility enhancing technologies are available
to formulators to improve the bioavailability of poorly water-soluble
molecules. The choice of a
bioavailability enhancing technology can be rationally based on an
understanding of the physical-chemical properties of the molecule augmented
with in-vitro measurements to help define the mechanism that is limiting
bioavailability. For example, the
bioavailability of molecules with poor dissolution rates can be improved with
straightforward solutions such as particle size reduction. Conversely, molecules that are poorly soluble
due to high crystal forces or high lipophilicity can be improved by the use of amorphous solid dispersions (ASD) or lipid-based formulations (LBF),
respectively. Commercial products have
been developed using each of these technologies.
This presentation will discuss the fundamental formulation and
processing considerations for obtaining a high-performing and physically- and chemically
stable formulation without excessive formulation or process iteration. In addition, in vitro methodologies for
choosing the most appropriate technology based on compound properties will be
presented. For each of these formulation
case studies, validation of the technology selection methods will be confirmed
with animal in-vivo data.
Learning Objectives
- Describe bioavailability enhancing (BAE) technologies
- Identify In vitro methodologies for choosing BAE technologies
- Discuss technology selection case studies
- Examine In vivo validation of methodologies